Resource Filter: Drug Development
Screening for Tumor Microtube-Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression
Date
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer
Date
.
Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor That Unleashes PD-1 Checkpoint and CAR T-Cell Immunotherapies
Date
Selective inhibition of canonical STAT3 signaling suppresses K-ras mutant lung tumorigenesis and reinvigorates anti-tumor immunity
Date
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma
Date
Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma
Date
INDUKINE Molecules Delivering Various Cytokines Utilize Unique Mechanisms of Action to Drive Anti-Tumor Efficacy in a Murine Syngeneic Tumor Model
Date
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for 1 Pancreatic Ductal Adenocarcinoma
Date
Profiling the tumor microenvironment through same-section fully automated spatial multiomics
Date
Discovery of WTX-518, an IL-18 Pro-drug That is Conditionally Activated Within the Tumor Microenvironment and Induces Regressions in Mouse Tumor Models
Date
